CLYM – climb bio, inc. (US:NASDAQ)

News

Climb Bio (CLYM) was upgraded by B. Riley Financial, Inc. to "strong-buy".
Climb Bio (CLYM) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $26.00 price target on the stock.
Climb Bio (CLYM) was upgraded by Truist Financial Corporation to "strong-buy".
Climb Bio (CLYM) was given a new $17.00 price target by Truist Financial Corporation.
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com